Dr. Glaucomflecken Explains: Oral PCSK9 Inhibitor Enlicitide (CORALreef Lipids)

Why It Matters

An effective oral PCSK9 inhibitor could broaden access to aggressive LDL‑lowering therapy, reducing reliance on injections and potentially reshaping cardiovascular risk‑management guidelines.

Key Takeaways

• Oral PCSK9 inhibitor Enlisticide reduces LDL by 57% in trial.
• Study enrolled 2,900 adults with prior cardiovascular events or high risk.
• 24‑week trial showed minimal LDL change with placebo (3%).
• Enlisticide offers potential non‑injectable alternative to existing PCSK9 therapies.
• Results published in NEJM may shift lipid‑lowering treatment guidelines.

Summary

The video features Dr. Glaucomflecken discussing a new oral PCSK9 inhibitor, Enlisticide, and its recent New England Journal of Medicine publication. The drug targets patients with familial hypercholesterolemia or elevated LDL—specifically those with prior cardiovascular events (LDL > 55 mg/dL) or at high risk for a first event (LDL > 70 mg/dL).

In a randomized, double‑blind study of 2,900 adults, participants received either once‑daily Enlisticide or placebo for 24 weeks. The trial reported a 57 % reduction in LDL cholesterol in the treatment arm versus a modest 3 % decline with placebo, underscoring the drug’s potency compared with existing injectable PCSK9 antibodies.

The dialogue, peppered with humor about arch‑nemesis specialties, highlights the clinical relevance: “What medication you think we should start on this patient? I’ve got one word—PCSK9.” The researchers’ findings, now in NEJM, lend credibility to the oral formulation, positioning it as a potential game‑changer for lipid management.

If the results are replicated in longer‑term studies, Enlisticide could simplify therapy, improve adherence, and reshape guideline recommendations, especially for patients reluctant to receive injections. Its oral route may also affect pricing dynamics and market competition among lipid‑lowering agents.

Original Description

This video in our partnership with @DGlaucomflecken explains a phase 3 clinical trial evaluating the efficacy of the oral PCSK9 inhibitor enlicitide in reducing LDL cholesterol levels over a 52-week period.

Visit nej.md/DrG37 for free access to the article.

#cardiology #medicaleducation #NEJM